Benjamin (Hrsg.) Bonavida
Tumor Cell Resistance In Cytotoxic Drug-Induced Apoptosis
Targeting Sensitizing Agents
Buch
Patients with various cancers are treated with conventional chemotherapeutic drugs and the majority responds well to such therapies. However, there is a subset of patients who does not respond initially and another subset who no longer responds to further treatments. Clearly, in those two subsets of patients, the cancer cells exhibit mechanisms of resistance. One of the main challenges facing us to date is to develop new therapies to treat patients with the resistant tumors. The development of new effective therapies will be dependent on delineating the biochemical, molecular, and genetic mechanisms that regulate tumor cell resistance. Such m…
Mehr
Beschreibung
Patients with various cancers are treated with conventional chemotherapeutic drugs and the majority responds well to such therapies. However, there is a subset of patients who does not respond initially and another subset who no longer responds to further treatments. Clearly, in those two subsets of patients, the cancer cells exhibit mechanisms of resistance. One of the main challenges facing us to date is to develop new therapies to treat patients with the resistant tumors. The development of new effective therapies will be dependent on delineating the biochemical, molecular, and genetic mechanisms that regulate tumor cell resistance. Such mechanisms have revealed gene products that directly regulate resistance and are targets for therapy. Of interest, several FDA-approved drugs were able to overcome drug resistance and have been successfully used clinically. They have been used as monotherapy or synergized with other therapies for the treatment of resistant tumors. This volume constitutes a total of twelve selective reviews by pioneer scientists in the field of cancer drug resistance. Specific mechanisms in drug resistance are reviewed and novel approaches are being proposed for therapeutic interventions. This volume is of general interest to scientists, clinicians, health care providers, and students.
CHF 211.00
Preise inkl. MwSt. und Versandkosten (Portofrei ab CHF 40.00)
V301:
Libri-Titel folgt in ca. 2 Arbeitstagen
Produktdetails
- ISBN: 978-1-4614-7069-4
- EAN: 9781461470694
- Produktnummer: 14457483
- Verlag: Springer-Verlag GmbH
- Sprache: Englisch
- Erscheinungsjahr: 2013
- Seitenangabe: 260 S.
- Masse: H24.1 cm x B16.0 cm x D1.9 cm 582 g
- Abbildungen: Book; 25 farbige Abbildungen
- Gewicht: 582
Über den Autor
Dr. Benjamin Bonavida is a professor at UCLA's David Geffen School of Medicine for the Department of Microbiology, Immunology, & Molecular Genetics. His other appointments include being a member of the Department of Defense Congressionally Directed Medical Research Program, Member of the National Cancer Institute's SPORE Program, member of the International Scientific Advisory Board of the Israel Cancer Research Foundation, to name a few. He's currently a scientific reviewer for several journals and a member of editorial boards including Journal of Clinical Immunology, International Journal of Oncology, and Cancer Biotherapy & Radiopharmaceuticals. In his career, he's published over 450 papers and reviews, and he's also edited two books with Springer in the past. For more information, please see the CV attached herewith.
34 weitere Werke von Benjamin (Hrsg.) Bonavida:
Targeting Sensitizing Agents
Ebook (PDF Format)
CHF 165.50
Targeting Sensitizing Agents
Ebook (PDF Format)
CHF 154.50
Targeting Sensitizing Agents
Ebook (EPUB Format)
CHF 169.00
Targeting Sensitizing Agents
Ebook (PDF Format)
CHF 165.50
Targeting Sensitizing Agents
Ebook (EPUB Format)
CHF 199.95
Targeting Sensitizing Agents
Ebook (EPUB Format)
CHF 169.00
Targeting Sensitizing Agents
Ebook (EPUB Format)
CHF 212.85
Targeting Sensitizing Agents
Ebook (EPUB Format)
CHF 169.00
Targeting Sensitizing Agents
Ebook (PDF Format)
CHF 187.50
Targeting Sensitizing Agents
Ebook (PDF Format)
CHF 165.50
Bewertungen
0 von 0 Bewertungen
Anmelden
Keine Bewertungen gefunden. Seien Sie der Erste und teilen Sie Ihre Erkenntnisse mit anderen.